San Francisco Chronicle

Huge study of genetics and diseases

- By Lauran Neergaard Lauran Neergaard is an Associated Press writer.

In a quest to end cookie-cutter health care, researcher­s are getting ready to recruit more than 1 million people for an unpreceden­ted study to learn how our genes, environmen­ts and lifestyles interact — and to finally develop custom ways to prevent and treat disease.

Why does one sibling get sick but not another? Why does a drug cure one patient but only cause nasty side effects in the next?

Finding out is a tall order. Today, diseases typically are treated based on what worked best in short studies of a few hundred or thousand patients.

“We depend on the average, the one-size-fitsall approach because it’s the best we’ve got,” said Dr. Francis Collins, director of the National Institutes of Health.

The NIH’s All Of Us project will push what’s called precision medicine, using traits that make us unique in learning to forecast health and treat disease. Partly it’s genetics. What genes do you harbor that raise your risk of, say, heart disease or Type 2 diabetes or various cancers?

But other factors affect that genetic risk: what you eat, how you sleep, whether you grew up in smog or fresh air, whether you sit at a desk all day or bike around town, whether your blood pressure is fine at a checkup but soars on the job, what medication­s you take.

Not to mention difference­s based on age, gender, race and ethnicity, and socioecono­mics.

Layering that informatio­n in what’s expected to be the largest database of its kind could help scientists spot patterns, combinatio­ns of factors that drive or prevent certain diseases — and eventually, researcher­s hope, lead to better care.

“The DNA is almost the easiest part,” Collins said. “It’s challengin­g to figure out how to put all that together to allow somebody to have a more precise sense of future risk of illness and what they might do about it.”

A pilot project is under way with more than 2,500 people. More than 50 sites around the country are enrolling people in this invitation-only phase.

If that goes well, NIH plans to open the study next spring to just about any U.S. adult who’s interested, with signup as easy as going online.

It’s a commitment. The study is scheduled to run for at least 10 years.

The goal is to enroll people from all walks of life, specifical­ly minorities who have been underrepre­sented in scientific research.

And unusual for observatio­nal research, volunteers will get results of their tests, which they can share with their own doctors.

“Anything to get more informatio­n I can pass on to my children, I’m all for it,” said Erricka Hager, 29, as she signed up last month at the University of Pittsburgh, the project’s first site. A usually healthy mother of two, she hopes the study can reveal why she experience­d high blood pressure and gestationa­l diabetes during pregnancy.

Heading the giant project is a former Intel executive who brings a special passion for widening access to the precision medicine that saved his life.

In college, Eric Dishman developed a form of kidney cancer so rare that doctors had no idea how to treat him, and predicted he had months to live. Only two studies of that particular cancer had ever been done, on people in their 70s and 80s.

“They’d never seen a 19-year-old with this disease,” said Dishman.

Yet he survived for two decades, trying one treatment after another. Then, as he was running out of options, a chance encounter with a genetics researcher led to mapping Dishman’s DNA — and the stunning discovery that his kidney cancer was geneticall­y more like pancreatic cancer. A pancreatic cancer drug attacked his tumors so he could get a kidney transplant.

“I’m healthier now at 49 than I was at 19,” said Dishman. “I was lucky twice over, really,” that he was offered an uncommon kind of testing and that it found something treatable.

Precision medicine is used most widely in cancer, as more drugs are developed that target tumors with specific molecular characteri­stics. Beyond cancer, one of the University of Pittsburgh’s hospitals tests every patient receiving a heart stent — looking for a genetic variant that tells whether they’ll respond well to a particular blood thinner or will need an alternativ­e.

The goal is to expand precision medicine.

“Why me?” is the question cancer patients always ask, said Dr. Mounzer Agha, an oncologist at the University of Pittsburgh Medical Center.

“Unfortunat­ely, I don’t have answers for them today,” said Agha, who says it will take the million-person study to finally get some answers. “It’s going to help them understand what are the factors that led to their disease, and it’s going to help us understand how to treat it better.”

And Collins expects surprises. Maybe, he speculates, Type 2 diabetes will turn out to be a collection of genetic subtypes that require varied treatments.

“This looks at individual responses to treatment in a way we couldn’t do previously with smaller studies.”

Volunteers will get standard health checks, answer periodic questionna­ires about their health, background and habits, and turn over electronic health records. They give a blood sample that, if they agree, will undergo DNA testing next year.

Eventually, researcher­s will ask some participan­ts to wear sensors that may measure blood pressure while people move around all day, or measure environmen­tal exposures, Collins said.

 ??  ??
 ??  ??

Newspapers in English

Newspapers from United States